Navigation Links
Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Date:6/27/2011

U.S. based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications.  It has licensed from Novogen Limited certain patent rights and know-how to use and exploit its technology in a wide range of wound healing applications.  Glycotex, Inc. is an 81 percent owned subsidiary of Novogen Limited. For more information, visit www.glycotexinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use.  Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure of our products to obtain such approval; uncertainties or differences in interpretation of clinical trial results; our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; genera
'/>"/>

SOURCE Glycotex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Glycotex, Inc. Expands Patent Portfolio in Advanced Wound Healing Indications
2. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
3. BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies
4. RF Technologies® Releases Code Alert® Quick Response® Wireless Call Solutions
5. Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
6. SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs
7. SCAI Releases First Report on Transradial Access for Angioplasty and Stenting
8. Mesa Labs Releases Major New DT Pro Software for Data Trace Data Loggers
9. Aethlon Medical Releases Shareholder Letter
10. Photonic Products Group, Inc. ("PPGI") Releases FY 2010 Financial Results
11. Applied Science Laboratories Releases Revolutionary Eye Tracking Analysis Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Heated dialogue in recent months about the ... treatments to Gilead,s new hepatitis C drug Harvoni® – ... questioning what it means to put a price on ... And while drug pricing is one of the most ... a general business and ethical standpoint – it is ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, Inc. ... (EMA) has granted Orphan Medicinal Product Designation ... for the treatment of fibrodysplasia ossificans progressiva ... genetic disease characterized by painful, recurrent episodes ... abnormal bone formation. This process, known as ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... Executive Officer, will be presenting at the 26 th ... Hotel in New York . The formal ... PM ET. In addition, Mr. Krakauer and Jorgen B. ... one-on-one meetings during the day. An audio ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... AstraZeneca (NYSE: AZN ) announced today that Judge Joseph ... that the substance patent protecting CRESTOR (RE37,314 – the ,314 patent) is valid ... committed by any Shionogi employee. The court also held the ,314 patent to ... , , ...
... June 29 Dr. Harry J. Guttman, Esq. , Of ... participant at the 2010 Central Regional Meeting of the American Chemical Society ...  The 2010 CeRMACS attracted over 400 participants and focused on small business ... , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has released its ... order to prepare for the wedding season. All of them ... , UWDress.com is a reliable company that has many years ... items -- formal wedding guest attire. This new collection comes ... and princess. As one of the leading companies in the ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
(Date:11/22/2014)... November 22, 2014 Lipitor lawsuits ( ... patients who allegedly developed Type 2 diabetes due to ... multidistrict litigation now underway in U.S. District Court, District ... court documents, the litigation will convene its next Status ... has directed Lead Counsel for Plaintiffs and Defendants to ...
(Date:11/22/2014)... 2014 The Sports Conflict Institute ... to its team of conflict resolution professionals. Baroff comes ... and referee. He has over 30 years experience as an ... “I'm very excited to connect with SCI and bring my ... to a program with a complete sports focus,” says Baroff. ...
Breaking Medicine News(10 mins):Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
... Health Management Systems,Inc. (HMS) announced today that it ... in Medford, Massachusetts, to provide coordination of,benefits services. ... than 150,000 MassHealth and Commonwealth Care members across,Massachusetts., ... will identify third party coverage for claims already ...
... CHARLOTTE, N.C., Dec. 12 CG Technology has ... better reflecting the depth,and breadth of services it ... high quality and standards of work, while focusing ... Carlisle & Gallagher Consulting Group (CG) is a ...
... 12 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that James L. Cox, M.D. ... Dr. Cox, reputation as a,preeminent authority in the ... that serves as the foundation for ATS 3f(R),tissue ...
... to six community organizations in ... underserved areas, WOODLAND HILLS, ... a total of $30,000 in end of,year donations to various food banks ... agencies in northern and,southern California to assist vulnerable populations., Blue Cross ...
... An improved understanding of the effects of regulation ... designed to advance entrepreneurship, according to a new ... for Entrepreneurship Public Policy report provides an overview ... system can discourage or encourage the entrepreneurial spirit. ...
... Dec. 11 Biodel Inc. (Nasdaq:,BIOD) today reported ... financial results, updated pipeline progress and disclosed 2008,objectives., ... public company, we advanced our pipeline,and achieved critical ... of Biodel. "The significant milestones reached include our,successful ...
Cached Medicine News:Health News:Network Health Awards Contract to HMS for Coordination of Benefits 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9
... 420 CPAP System includes the 420E Auto-CPAP ... can enjoy the advantages of the worlds ... devices. The GoodKnight 420E model records up ... includes other features of the 420S model. ...
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Safety Blood Collection Sets are supplied in three packaging variations, either with or without Luer Adapter and respectively a version with Luer Adapter and Tube Holder....
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
Medicine Products: